TipRanks
Takeda Pharmaceutical Co Ltd (JP:4502)
:4502
Want to see JP:4502 full AI Analyst Report?

Takeda Pharmaceutical Co (4502) Price & Analysis

10 Followers

4502 Stock Chart & Stats

¥5813.00
¥121.00(2.14%)
At close: 4:00 PM EDT
¥5813.00
¥121.00(2.14%)

Bulls Say, Bears Say

Bulls Say
Strong Cash GenerationSubstantial operating and free cash flow gives Takeda capacity to fund research, launches, debt service, and shareholder returns internally. This strengthens resilience across its product cycle and supports continued investment in growth opportunities without relying solely on external financing.
Diversified Growth PipelineGrowth from recently launched products and multiple late-stage assets provides avenues to offset mature-product erosion. Regulatory progress and differentiated clinical results could broaden Takeda’s commercial base and sustain revenue growth as newer medicines become a larger share of sales.
Improving Leverage And Solid Operating MarginsImproving leverage supports financial flexibility while strong gross and operating margins indicate meaningful economics in Takeda’s global branded-pharmaceutical portfolio. Together, these factors provide a healthier platform for funding pipeline investment and absorbing product-cycle volatility over the medium term.
Bears Say
Constant-Currency Revenue PressureUnderlying performance was slightly negative after removing currency effects, showing that reported growth currently overstates operational momentum. Investment behind launches, mature-product headwinds, and generic erosion may continue to pressure organic growth until newer products scale more materially.
Mature Product And Exclusivity ErosionLoss of exclusivity creates a structural drag on branded drug revenue as generic competition reduces sales from mature products. This makes Takeda increasingly dependent on successful launches, lifecycle management, and pipeline conversion to replace declining established medicines.
Thin And Volatile Bottom-Line ReturnsLow and variable net profitability indicates that strong gross and operating economics are not consistently translating into shareholder returns. This reduces earnings resilience and leaves less room for unexpected costs, investment increases, or product setbacks to be absorbed without affecting performance.

Takeda Pharmaceutical Co News

4502 FAQ

What was Takeda Pharmaceutical Co Ltd’s price range in the past 12 months?
Takeda Pharmaceutical Co Ltd lowest stock price was ¥4102.00 and its highest was ¥6306.00 in the past 12 months.
    What is Takeda Pharmaceutical Co Ltd’s market cap?
    Takeda Pharmaceutical Co Ltd’s market cap is ¥9.93T.
      When is Takeda Pharmaceutical Co Ltd’s upcoming earnings report date?
      Takeda Pharmaceutical Co Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 10 days.
        How were Takeda Pharmaceutical Co Ltd’s earnings last quarter?
        Takeda Pharmaceutical Co Ltd released its earnings results on Jul 30, 2026. The company reported ¥71.65 earnings per share for the quarter, beating the consensus estimate of ¥54.38 by ¥17.27.
          Is Takeda Pharmaceutical Co Ltd overvalued?
          According to Wall Street analysts Takeda Pharmaceutical Co Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Takeda Pharmaceutical Co Ltd pay dividends?
            Takeda Pharmaceutical Co Ltd pays a Semiannually dividend of ¥102 which represents an annual dividend yield of 3.25%. See more information on Takeda Pharmaceutical Co Ltd dividends here
              What is Takeda Pharmaceutical Co Ltd’s EPS estimate?
              Takeda Pharmaceutical Co Ltd’s EPS estimate is 46.2.
                How many shares outstanding does Takeda Pharmaceutical Co Ltd have?
                Takeda Pharmaceutical Co Ltd has 1,602,141,400 shares outstanding.
                  What happened to Takeda Pharmaceutical Co Ltd’s price movement after its last earnings report?
                  Takeda Pharmaceutical Co Ltd reported an EPS of ¥71.65 in its last earnings report, beating expectations of ¥54.38. Following the earnings report the stock price went down -2.206%.
                    Which hedge fund is a major shareholder of Takeda Pharmaceutical Co Ltd?
                    Currently, no hedge funds are holding shares in JP:4502
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Company Description

                      Takeda Pharmaceutical Co Ltd

                      Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.

                      Takeda Pharmaceutical Co (4502) Earnings & Revenues

                      4502 Company Deck

                      4502 Earnings Call

                      Q1 2026
                      0:00 / 0:00
                      Earnings Call Sentiment|Positive
                      The call presented a mix of modest near-term CER declines and cash-flow timing effects against substantial positive developments: strong FX-driven reported results, confirmation of transformation-led funding for launches, multiple imminent regulatory and commercial milestones (ORZEYFUL approval in China; rusfertide priority review; superior zasocitinib data), and a robust late-stage pipeline with several programs moving to pivotal stages. While Q1 contained some one-time impacts, transitional investment effects and product-specific headwinds, the combination of pipeline momentum, launch readiness and a maintained full-year financial outlook suggests the company is positioned to convert R&D progress into revenue growth later in the year.View all JP:4502 earnings summaries

                      4502 Stock 12 Month Forecast

                      Average Price Target

                      ¥6,966.67
                      ▲(19.85% Upside)
                      {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4010":"¥4,010","7101":"¥7,101","4782.75":"¥4,782.8","5555.5":"¥5,555.5","6328.25":"¥6,328.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥7K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6966.666666666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥7K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥7K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4010,4782.75,5555.5,6328.25,7101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5731,5836.307692307692,5941.615384615385,6046.923076923077,6152.2307692307695,6257.538461538462,6362.846153846154,6468.153846153846,6573.461538461538,6678.7692307692305,6784.076923076923,6889.384615384615,6994.692307692308,{"y":7100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5731,5826.051282051282,5921.102564102564,6016.153846153846,6111.205128205128,6206.25641025641,6301.307692307692,6396.358974358974,6491.410256410256,6586.461538461538,6681.51282051282,6776.564102564102,6871.615384615384,{"y":6966.666666666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5731,5813.2307692307695,5895.461538461538,5977.692307692308,6059.923076923077,6142.153846153846,6224.384615384615,6306.615384615385,6388.846153846154,6471.076923076923,6553.307692307692,6635.538461538461,6717.7692307692305,{"y":6800,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4115.034,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4011.675,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4355.561,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4670.468,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5160.215,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5596.833,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5786.722,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5148.885,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4797.043,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5061.416,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5418.173,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5744.462,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5731,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Sumitomo Dainippon Pharma Co
                      ―
                      ―
                      Eisai Co
                      ―
                      ―
                      ―
                      ―
                      ―
                      Shionogi & Co
                      ―
                      ―
                      Nippon Shinyaku Co., Ltd.
                      ―
                      ―
                      Popular Stocks